KBFS
ALNY icon

Kohmann Bosshard Financial Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kohmann Bosshard Financial Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$235 – 304
2024
Q4 		$235 Buy
+1
New +$263 ﹤0.01% 719

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kohmann Bosshard Financial Services's ALNY Position: Q1 2025 in Review

Kohmann Bosshard Financial Services sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 1 share — an estimated $235 sold.

Kohmann Bosshard Financial Services first reported a position in ALNY in Q4 2024 and held it in 1 quarter. The position peaked at $235 in Q4 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Kohmann Bosshard Financial Services reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Kohmann Bosshard Financial Services sold 1 Alnylam Pharmaceuticals share in Q1 2025, an estimated $235.
  • Kohmann Bosshard Financial Services first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Kohmann Bosshard Financial Services's Alnylam Pharmaceuticals position peaked at $235 in Q4 2024.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Kohmann Bosshard Financial Services's 13F filing for Q1 2025, filed 12 May 2025.